Earnings Momentum: Social media chatter centers on Eli Lilly's recent quarterly results, which exceeded estimates thanks to surging demand for Mounjaro and Zepbound. Revenue growth reflected strong patient uptake, prompting several analysts to lift price targets. The stock closed the session up over 2 percent.
Competitive Edge: Observers note how Eli Lilly's position in the weight-loss market is pressuring rivals, with one major bank downgrading a competitor amid shifting shares. Technical levels around $1,100 are viewed as key support by market watchers. Broader conversation emphasizes pipeline additions in neuroscience through recent acquisitions.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly Insider Trading Activity
Eli Lilly insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
- ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
- ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
- DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Eli Lilly Revenue
Eli Lilly had revenues of $23B in Q2 2026. This is an increase of 47.67% from the same period in the prior year.
You can track LLY financials on Quiver Quantitative's LLY stock page.
You can access data on LLY stock through the Quiver Quantitative API.
Eli Lilly Congressional Stock Trading
Members of Congress have traded $LLY stock 8 times in the past 6 months. Of those trades, 4 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
- REPRESENTATIVE MICHAEL A. RULLI sold up to $15,000 on 07/01.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $115,000 on 06/10, 04/14 and 0 sales.
- REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/02 and 0 sales.
- SENATOR ALAN ARMSTRONG sold up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Eli Lilly Hedge Fund Activity
We have seen 2,577 institutional investors add shares of Eli Lilly stock to their portfolio, and 1,712 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 12,598,524 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,111,047,641
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 6,001,955 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,198,924,885
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,759,507 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $4,509,265,481
- WELLINGTON MANAGEMENT GROUP LLP removed 2,428,108 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $2,912,345,578
- FMR LLC added 2,121,444 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $2,544,523,576
- LILLY ENDOWMENT INC removed 1,520,000 shares (-1.7%) from their portfolio in Q2 2026, for an estimated $1,823,133,600
- SG AMERICAS SECURITIES, LLC added 1,331,427 shares (+204.1%) to their portfolio in Q2 2026, for an estimated $1,596,953,486
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Eli Lilly Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 11 analysts offer price targets for $LLY in the last 6 months, with a median target of $1350.0.
Here are some recent targets:
- Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
- Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
- Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
- Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
- Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
- David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
- Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
